BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

Core Viewpoint - BioXcel Therapeutics, Inc. has regained compliance with Nasdaq's market value of listed securities requirement, indicating a positive development for the company's listing status [1][2]. Company Compliance - The company was previously notified on March 20, 2025, that it was not in compliance with Nasdaq Listing Rule 5550(b)(2) due to its market value being below $35.0 million for 30 consecutive business days [2]. - Following a hearing on May 1, 2025, the company received an exception to regain compliance, and on September 17, 2025, Nasdaq confirmed that the company has met all listing requirements [2]. Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company that utilizes artificial intelligence to develop transformative medicines in neuroscience [3]. - The company's subsidiary, OnkosXcel Therapeutics, focuses on immuno-oncology drug development [3]. - BioXcel employs a drug re-innovation approach, leveraging existing approved drugs and big data to identify new therapeutic indications [3].